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Abstract 
Background 
Provoked vestibulodynia (PVD) is a highly prevalent condition characterized by acute recurrent 
pain located at the vaginal entrance in response to pressure application or attempt of vaginal 
penetration. Despite a wide variety of treatments offered to women with PVD, a high proportion 
of women are refractory to conventional treatment. Transcranial direct-current stimulation 
(tDCS) is a non-invasive brain stimulation technique that has been shown effective for 
improving various chronic pain conditions. Growing evidence suggests that the central nervous 
system (CNS) could play a key role in PVD. Targeting the CNS could be a promising treatment 
avenue for women suffering from PVD. 
Objective 
The purpose of this study was to evaluate and compare the efficacy of active and sham tDCS in 
reducing pain intensity during intercourse in women with PVD. 
Study design 
We conducted a triple-blind, parallel group, randomized controlled trial (RCT). Women, aged 
between 17-45 years and diagnosed with PVD by a gynecologist using a validated protocol were 
randomized to 10 sessions of either active tDCS (intensity = 2mA) or 10 sessions of sham tDCS, 
over a 2-week period. Both active and sham tDCS were applied for 20 minutes, with the anode 
positioned over the primary motor cortex (M1), and the cathode, over the contralateral 
supraorbital area. Outcome measures were collected at baseline, 2 weeks after treatment and at 3-
month follow-up by an evaluator blinded to group assignation. The primary objective was pain 
intensity during intercourse, as assessed with a numerical rating scale. Secondary outcomes 
focused on sexual function and distress, vestibular sensitivity, psychological distress, treatment 
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satisfaction and patient impression of change. Statistical analyses were conducted on the 
intention-to-treat basis, and treatment effects were evaluated using a mixed linear model for 
repeated measures. 
Results 
A total of 40 women were randomly assigned to received either active (n=20) or sham (n=20) 
tDCS treatments between November 2014 and February 2016. Baseline characteristics were 
similar between active and sham tDCS groups. Active tDCS did not significantly reduced pain 
during sexual intercourse compared to sham tDCS 2 weeks after treatment (p=0.84) and at 
follow-up (p=0.09). Mean [95% CI] baseline and 2-week assessment pain intensity were 
respectively 6.8 [5.9 - 7.7] and 5.6 [4.7 - 6.5] for active tDCS (p=0.03) versus 7.5 [6.6 - 8.4] and 
5.7 [4.8 - 6.6] for sham tDCS (p=0.001). Non-significant differences between the two groups 
were also found in regards to sexual function and distress after treatment (p>0.20) and at follow-
up (p>0.10). Overall, at 2-week assessment 68% women assigned to active tDCS reported being 
very much, much or slightly improved compared to 65% of women assigned to sham tDCS 
(p=0.82), and still comparable at follow-up 42% versus 65%, respectively (p=0.15). 
Conclusion 
Findings suggest that active tDCS is not more effective than sham tDCS for reducing pain in 
women with PVD.  Likewise, no significant effects were found on sexual function, vestibular 
sensitivity or psychological distress. 
 
Trial registration 
Clinicaltrials.gov NCT02543593; registration date: September 4, 2015. 
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Introduction 
Chronic pain associated to female reproductive system is a neglected health problem.1 By age 40, 
nearly 10% of women will develop vulvar pain symptoms.2 Provoked vestibulodynia (PVD), the 
most frequent cause of pre-menopausal dyspareunia,3 is characterized by a recurrent sharp pain 
at vulvar entrance (vestibule) in response to pressure or vaginal penetration attempt. The current 
medical approach for PVD relies on empirical treatment options, including localized (i.e. topical 
lidocaine , physical therapy), systemic (i.e. tricyclic antidepressants, anticonvulsants), 
psychotherapeutic (i.e. cognitive behavioral therapy, sex therapy), and ultimately, surgical 
(vestibulectomy) interventions.4 
Women with PVD not only exhibit increased vulvar sensibility, but also have lower pain 
threshold and tolerance to other body regions, not restricted to the vestibule area.5-7 Because 
PVD pathophysiology has been suggested to not be limited to the vulvar vestibule, central pain 
processing alterations similar to other chronic pain syndrome, like fibromyalgia,8,9 irritable 
bowel syndrome,10 and idiopathic back pain11 might be involved. 
More recently, neuromodulation treatment options namely transcranial direct-current stimulation 
(tDCS) has been proposed as another favorable therapeutic step for women with vulvodynia.12 
However, the evidence supporting the use of tDCS in this population is lacking. Treatments 
targeting the nervous system could be a promising therapeutic approach to reduce pain during 
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intercourse for women with PVD given the central nervous system (CNS) alterations postulated 
in this population.5-7 
To our knowledge, the effect of tDCS for reducing pain in women with vulvodynia has only 
been documented in one case study,13 which described remarkable long-lasting pain relief using 
tDCS in a woman suffering from severe chronic vulvar pain refractory to many empirical 
treatments. Based on Cecilio et al’s observations,13 it could be hypothesized that active tDCS 
treatment compared to sham would significantly reduce pain during intercourse in women with 
PDV (2-week post-treatment and 3-month follow-up compared to baseline assessment). 
The main purpose of this study was to evaluate and compare the efficacy of active and sham 
tDCS in reducing pain intensity during intercourse in women with PVD. We also compared the 
effects of both interventions for sexual function, vestibular sensitivity, psychological distress, 
treatment satisfaction and patient’s global impression of change. 
 
Materials and Methods 
Study design 
A triple-blind (assessor, patient, and treatment provider) randomized placebo-controlled trial was 
conducted. Eligible women were randomly assigned to receive either active or sham tDCS. 
Outcome assessments were conducted at baseline, 2 weeks after treatment and 3 months after 
treatment. The study protocol received ethical approval from the Comité d’éthique de la 
recherche en santé chez l’humain du CHUS, Sherbrooke, Québec. Each participant provided 
written informed consent before participating in the study. The study protocol was registered at 
clinicaltrials.gov (NCT02543593) and published in the journal Trials.14 
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Participants 
Premenopausal women aged between 17-40 years old suffering from pain during sexual 
intercourse were recruited at the Research Center of the Centre hospitalier universitaire de 
Sherbrooke between November 2014 and February 2016. Participants’ eligibility was first 
authenticated during a telephone interview with the research coordinator. Thereafter,  to further 
assess eligibility and confirm PVD diagnosis, a gynecological assessment was performed by a 
gynecologist of the research team (GW, YB or IG) following a standardized protocol.15,16 
Women were found eligible if they experienced, in the last 6 months, moderate to severe pain 
(>5/10) in at least 90% of attempted sexual intercourse. Women with other urogynecological 
conditions (e.g. urinary tract or vaginal infection) or pelvic pathology associated with pelvic pain 
(e.g. deep dyspareunia), having additional health issues or contraindications to tDCS (i.e. family 
history of epilepsy) were excluded from participating in the study. 
 
Intervention 
Participants were randomized to receive 10 sessions of either active/anode or sham/placebo 
tDCS over a period of fourteen days. tDCS treatments were given once a day, during weekdays 
(Monday to Friday). Each session lasted 20 minutes17-21 and was administered by a research 
professional experienced in tDCS. The treatment provider was not involved in patient assessment 
and was blinded to the treatment allocation by selecting a preset program of the tDCS device 
(NeuroConn DC stimulator, Model 0008, Ilmenau, Germany). Two electrodes were applied to 
the subject’s scalp; the anode was placed over the motor cortex (M1)22 and the cathode over the 
contralateral supraorbital area.17-19,21,22 Saline solution (77mM NaCl) was used to soak the 
synthetic sponge electrode covers (35cm2). For the active tDCS condition, the intensity of the 
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stimulation was set at 2 mA for the entire duration of treatment.13,17,23 These parameters have 
been used with many subjects in several laboratories without side effects (see24 for review) apart 
from a slight sensation and erythema under the electrodes and possible headache in the hours 
following the treatment. For the sham tDCS condition, the electrodes were positioned in the same 
areas as for the active group. The intensity was set at 2 mA for the first 30 seconds of 
treatment,21 after which the stimulation stopped automatically. Just as for the experimental group 
(active tDCS), participants in the control group (sham tDCS) were advised that a brief tingling 
sensation may be felt at the beginning of the treatment. This method was  effective for preserving 
subject and investigator blinding in previous studies.25,26 
 
Data collection 
Outcome assessment 
As recommended by the Initiative on Methods, Measurement, and Pain Assessment in Clinical 
Trials (IMMPACT),27,28 multiple dimensions of pain have been targeted in order to adequately 
evaluate the effectiveness of tDCS in reducing pain during intercourse in women with PVD. 
Baseline characteristics were collected during a structured interview at pretreatment assessment. 
Assessments were collected at baseline, 2-weeks and follow-up, except for patient’s treatment 
satisfaction and impression of change (collected after the end of treatments only). Participants 
received CAD$20 after each assessment visit for a possible total of CAD$60. 
 
Pain during intercourse 
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Participants were asked to evaluate their mean pain intensity during intercourse since the last 
assessment on a 0-10 verbal numeric rating scale (NRS0-10), 0 being no pain, and 10 the worst 
pain ever experienced. 
 
Questionnaires 
Standardized and validated questionnaires included pain quality (McGill-Melzack Pain 
Questionnaire),29,30 sexual functioning (Female Sexual Function Index),31 sexual distress 
(Female Sexual Distress Scale),32 sexual satisfaction (Global Measure of Sexual Satisfaction),33 
and patient’s treatment satisfaction and impression of change (Patient’s Global Impression of 
Change questionnaire)34,35 were also completed. Psychological distress included questionnaires 
focusing on vaginal penetration (Vaginal Penetration Cognition Questionnaire),36 catastrophizing 
(Pain Catastrophizing Scale),37 anxiety (State-Trait Anxiety Inventory of Spielberger and Pain 
Anxiety Symptoms Scale),38,39 and depression (Beck Depression Inventory)40. 
 
Vestibular sensitivity 
The third International Consultation on Sexual Medicine underlined the importance of assessing 
vestibular sensitivity.41 Our laboratory recently developed an algometer to measure vulvar pain 
threshold and tolerance in women with PVD. A gradual pressure (0 to 1000 grams) was applied 
to three distinct points of the vestibule at the 3, 6 and 9 o’clock positions.42 Each  pressure point 
was applied randomly (e.g. 3,6,9 or 3,9,6 or 6,9,3.). During this procedure, each participant was 
asked to indicate when they started to feel pain (pressure pain threshold; PPT) and, subsequently, 
the maximal pressure they could tolerate (pressure pain tolerance; PPTol).43 Both PPT and PPTol 
were identified using a Computerized Visual analog scale (COVAS) throughout the test. PPT 
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was determined when the participant started to move the COVAS from 0 (no pain), and PPTol 
was established when the participant reached 10 (most intense pain tolerable). This assessment 
has shown good reliability and validity.42 
 
Adverse events 
To report participants’ adverse events during tDCS treatment, at each treatment session, the 
treatment provider noted participants’ side effects; subjects were also asked to report any adverse 
events experienced during or after each tDCS session in a 2-week diary. 
 
Sample size calculation 
A sample size of 34 participants was judged sufficient to detect a clinical minimal significant 
difference of 227,44 on the NRS (α=0.05; β=0.80, standard deviation of 2.0, based on the data 
from previous tDCS reports21,45). This estimation of treatment effect was conservative 
considering that tDCS demonstrated an overall effect on pain reduction of 4.3 points46 in various 
chronic pains and that the available case study in a woman with vulvodynia showed a reduction 
of 10 points.13 To account for potential dropouts, a total of 40 subjects were recruited. This 
estimated dropout rate (<15%) was based on available studies and our own RCT experience in 
women with PVD.47-49 
 
Randomization and blinding 
After the baseline assessment, the participants were randomized into either the active or sham 
tDCS treatment (ratio 1:1) using random permuted block sizes of two and four. The allocation 
was managed by an independent individual of our research team following a computer-generated 
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randomization list drawn up by an independent statistician. Participants, investigators, 
physiotherapist assessors and treatment provider remained blinded to group allocation and 
therefore, could not influence the process in any way. 
 
Statistical Analysis 
Baseline sample characteristics are presented using descriptive statistics. Analyses were done in 
intention-to-treat. The effects of treatment on pain, sexual function and psychological distress 
were examined using a mixed linear model for repeated measures. One of the factors was the 
GROUP (treatment group: active tDCS and control group: sham tDCS), while the repeated factor 
was TIME (baseline, 2-week post-treatment, and 3-month follow-up assessments). Treatment 
efficacy was judged on the basis of a significant GROUP*TIME interaction.50 For some data-
sets, logarithmic transformation was required to correct the distribution to normal (Pain quality, 
Vaginal control cognition, Anxiety-State, Depression, and Algometer). After analysis, results 
were converted back to their original scale. The difference between the two groups regarding 
satisfaction and PGIC was also assessed using mixed linear model for repeated measures. All 
statistical analyses were conducted at a significance level of 0.05 using Bonferroni adjustment 
for time factor. Analyses were conducted with SPSS Statistics for Windows, version 18.0 (SPSS 
Inc., Chicago, Ill, USA). 
 
Results 
Participants 
A total of 202 patients were screened for study eligibility from November 2014 through February 
2016. Of these, 111 women were excluded due to ineligibility, and 42 refused to participate prior 
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to gynecological assessment. Another 6 women were excluded at gynecologist assessment due to 
deep dyspareunia diagnosis (n=3), and negative Q-tips test (n=3). After receiving their PVD 
diagnosis, three additional women refrained to take part in the study. As a result, 40 participants 
were consented, scheduled for baseline assessment, randomly assigned to receive active tDCS 
(n=20) or sham tDCS (n=20), and reschedule for 2-week and follow-up assessments. One 
participants’ data could not be considered in the analyses because she did not attempt any 
vaginal penetration after receiving treatments. All participants were fully compliant to study 
treatment and assessments as planned in the study protocol. None of the active or sham group 
received other therapeutic interventions during the study. Figure 1 shows the trial flow diagram. 
Baseline characteristics are presented in Table 1. Participants’ characteristics were well matched 
for both treatment groups in regard to age, education, civil status, pain intensity and frequency, 
age at first intercourse attempt, number of sexual partners, relationship and pain duration, PVD 
subtype, and use of oral contraceptive. 
 
Primary outcome 
Mean pain intensity scores during intercourse for each assessment are illustrated in Figure 2. 
Women assigned to both interventions reported a significant pain intensity reduction from 
baseline to post-treatment assessment (reduction of 1.2 points in active, 95% CI 0.4-2.1; p=.03 
and 1.8, 95% CI 0.8-2.8 in sham tDCS; p=.001). In addition, women assigned to sham treatment 
reported a significant pain intensity reduction from baseline to follow-up assessment (reduction 
of 2.5 points, 95% CI 1.4-3.7; p<.001). However, there was no statistical significant difference 
between treatment groups at each assessment (p=.84 and .09), respectively. 
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Secondary outcomes 
Non-significant differences were found at baseline between the two groups in the secondary 
outcomes except for state-anxiety which was higher in the active tDCS group than in the placebo 
group. A significant reduction of sexual distress, catastrophizing, pain anxiety and improvement 
in sexual function were observed in both treatments from baseline to follow-up assessments. 
Again, there was no statistical difference between women assigned to active and sham tDCS (p-
values>.08). Even though there was a significant difference between groups at post-treatment in 
catastrophizing (p=.02), pain anxiety (p=.03), and at follow-up in pain quality (p=.004), active 
tDCS did not result in a significant advantage in any measured outcome at any time point, 
compared to sham tDCS. Questionnaire scores are presented in Table 2. Interestingly, patient 
treatment satisfaction and impression of change were similar between groups (p-values>.14). 
As shown in Table 3, compared to sham, active tDCS did not significantly improve vestibular 
sensitivity (PPT and PPTol) at any assessments (p-values>.07), although pressure pain tolerance 
measured at the 6 o’clock position at follow-up assessment who was higher in sham group 
(p=.02). 
 
Blinding integrity 
Treatment blinding was effective for participants but not for the tDCS operator (see Table 4). 
Forty-two percent of women in active, and 45% of women in sham treatment group correctly 
identified which treatment they received (p=.5).26,45 However, tDCS operator correctly identified 
active treatment in 84%, and sham treatment in 60% of the cases (p=.008). 
 
Adverse effects 
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Mild and transitory side-effects, commonly found in the literature about tDCS intervention,24 
were reported by participants in both groups (see Table 5). During treatment sessions, participant 
assigned to sham treatment reported more tingling sensation under the cathode (p=.02), while 
burning sensation under the cathode and erythema24 under the anode were observed more often 
by participants assigned to active treatment (both p=.04). In opposition, there was no difference 
between groups regarding reported adverse events between treatment sessions, such as fatigue 
(p=.30), headache (p=.60),24 dizziness (p=.50) or nausea (p=.20). 
 
Comment 
To our knowledge, this is the first RCT evaluating tDCS efficacy for reducing pain in women 
with PVD. Our results show that active tDCS does not significantly reduce pain during 
intercourse nor improve sexual function or distress, vestibular sensitivity or psychological 
distress, compared to sham/placebo. 
 
Although tDCS has been shown effective to reduce pain in multiple chronic pain 
conditions,18,19,23,53-55 its efficacy to reduce pain during intercourse in women with PVD was not 
found substantiated. While women assigned to sham treatment reported a clinically significant 
pain intensity reduction from baseline to follow-up assessment (reduction of 2.5 points), this was 
not observed in the active group. Notably, the pain intensity reduction did not significantly or 
clinically differ between groups. The absence of group difference is not a sample size issue, as 
we had adequate statistical power to detect clinically relevant differences; hence type II error is 
not a valid explanation for our findings. 
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Our results coincide with a recently updated Cochrane review now showing non-significant 
difference between active and sham tDCS in chronic pain reduction.56 Our trial also challenges 
the observation of tDCS efficacy in reducing vulvar pain as published by Cecilio et al.13 
However, it must be highlighted that the woman described in Cecilio et al.’s case study was 
suffering from generalized unprovoked vulvodynia. Because these are two different subtypes of 
vulvodynia, it is possible that tDCS might be effective in one condition but not in the other. 
Previous authors clearly showed the analgesic effect of tDCS in fibromyalgia,23 spinal cord 
injury,18,21 and post-stroke pain53,57 using RCTs. It is possible that tDCS has greater effect for 
unprovoked types of pain, as observed by Cecilio et al.,13 than for provoked pain conditions like 
PVD. 
 
Mechanisms underlying placebo analgesia are only partly understood. It has been shown that 
expectation of relief contributes to placebo responses.63 Another possible explanation is the 
support provided throughout the study. PVD is indeed a meaningful threat that interferes with 
many aspects of women’s lives (i.e. sexual satisfaction, sexual self-esteem, psychological and 
sexual distress).64 Given that PVD is often misdiagnosed or even ignored, women participating 
in our study have had prompt access to a gynecologist, which should normally take at least a year 
in Quebec’s health care system. Meeting the same physiotherapist at each assessment and the 
same treatment provider on a daily basis over a two-week period, both female specialized in 
vulvar pain, allowed the participants to discuss of their sexual problematic with confidence. This 
may partially explain the changes observed in both interventions for sexual functioning, sexual 
distress, catastrophizing, and pain anxiety. Behavioral approaches such as systematic 
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desensitization and attentive listening were respectively found effective for pain management in 
vaginismus65 and elderly.66 
 
A substantial portion of women with PVD is reported to present pain hypersensitivity at both 
vulvar5-7 and extra-genital regions (i.e. forearm, arm, fingers, thigh, shin),6,7 suggesting that not 
only peripheral sensitization but also generalized central abnormalities are involved in PVD.67 
As proposed by Zhang et al.,68 similar chronic pain alterations exist in several patients with 
vulvodynia. However, in their publication, the authors did not distinguish women with provoked 
pain from those with unprovoked pain. To determine whether PVD-subgroups can benefit more 
than others from tDCS, the relationship between the hypoalgesic effect noted after tDCS 
treatments and other variables such as emotional component of pain and central processing 
alteration should be investigated.  
 
The strength of our study relies on its rigorous methodology. We minimised potential bias by 
including a recommended credible sham treatment, randomizing treatment allocation, and 
blinding the participants, treatment provider, outcome assessor, and statistician. In addition, to 
avoid information bias, we followed several authors’ suggestions74,75 stating that the treatment 
assessor blinding is compromised at 2 mA intensity. Therefore, in our study, the treatment 
provider was not involved in any outcome assessments. Despite all these efforts made to 
minimise bias our trial still have some limitations. Women’s menstrual cycle was not controlled 
during the study, even though it is known that pain perception changes across menstrual cycle.76 
However, this variability in subject’s pain evaluation and perception should be balanced between 
groups due to randomized treatment allocation. Another limitation might be attributable to 
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inconsistency in pain evaluation and information bias, especially when the participant had to 
recall relatively distant experiences. To counterbalance this potential memory bias, subjects were 
asked to complete a 4-week logbook (during the treatment period and two weeks after) in which 
they had to report if they experienced any pain in the vulvar region, whether related to 
intercourse. 
 
Conclusion 
Active tDCS did not confer benefits over sham tDCS in pain or function in women with PVD. 
Although it remains possible that a subpopulation of women with PVD could benefit from tDCS, 
our findings do not support the use of tDCS for these patients. 
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Tables 
 
Table 1 – Baseline characteristics by treatment group 
 
Variable 
Active tDCS 
(n=20) 
Sham tDCS 
(n=20) 
Age at randomization, ya 22 (20 – 24) 22 (20 – 24) 
Education, n (%) 
Elementary 
High school 
Professional study diploma 
College 
Baccalaureate 
 
1 (5) 
4 (20) 
1 (5) 
12 (60) 
2 (10) 
 
0 
5 (25) 
1 (5) 
9 (45) 
5 (25) 
Civil status, n (%) 
Relationship 
Civil union 
Married 
 
11 (55) 
8 (40) 
1 (5) 
 
11 (55) 
8 (40) 
1 (5) 
Pain intensity, NRS0-10
a 6.5 (6.0 – 7.9) 7.0 (7.0 – 8.8) 
Age at first intercourse attempt, ya 16 (15 – 18) 17 (15 – 18) 
Sexual partners, n 3 (1 – 5) 3 (1 – 5) 
Relationship duration, ya 2.8 (1.7 – 4) 2.3 (1.2 – 4.3) 
Pain duration, ya 3.0 (1.6 – 5.0) 2.0 (1.6 – 4.0) 
Intercourse frequency, wka 0.8 (0.3 – 2.9) 1.0 (0.2 – 2.0) 
Oral contraceptive, n (%) 20 (100) 19 (95) 
PVD Subtype, n (%) 
Primary 
Secondary  
 
5 (25)  
15 (75) 
 
5 (25) 
15 (75) 
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Table 2 – Pain, sexual function, psychological distress, treatment satisfaction and patient 
global impression of change by treatment group 
 
 Treatment group   
 Active tDCSa Sham tDCSa Difference between groups 
Outcomes n = 19 n = 20 P value b 
Pain qualityc 
Baseline 
2-week assessment 
Follow-up assessment 
 
23.6 (17.8 - 31.4) 
22.5 (17.0 - 29.9) 
22.3 (16.8 - 29.6) 
 
22.8 (17.3 - 30.0) 
17.3 (13.1 - 22.8) 
12.4 (9.4 - 16.3)*** 
 
.85 
.19 
.004†† 
Sexual functioningd 
Baseline 
2-week assessment 
Follow-up assessment 
 
20.4 (17.8 - 23.0) 
23.9 (21.3 - 26.5)** 
23.4 (20.8 - 26.0)* 
 
20.1 (17.6 - 22.6) 
22.2 (19.7 - 24.7) 
23.9 (21.3 - 26.4)** 
 
.87 
.35 
.79 
Sexual distresse 
Baseline 
2-week assessment 
Follow-up assessment 
 
30.1 (24.2 - 35.9) 
23.4 (17.6 - 29.2)* 
20.8 (15.0 - 26.6)** 
 
27.1 (21.4 - 32.8) 
18.8 (13.1 - 24.4)** 
15.4 (9.7 - 21.0)*** 
 
.47 
.26 
.19 
Sexual satisfactionf 
Baseline 
2-week assessment 
Follow-up assessment 
 
21.4 (18.3 - 24.5) 
22.8 (19.7 - 25.9) 
23.2 (20.1 - 26.3) 
 
21.7 (18.7 - 24.7) 
24.2 (21.2 - 27.2) 
25.8 (22.7 - 28.8)* 
 
.88 
.52 
.24 
Vaginal control cognitiong 
Baseline 
2-week assessment 
Follow-up assessment 
 
3.6 (3.0 - 4.1) 
4.1 (3.6 - 4.5) 
4.1 (3.6 - 4.5) 
 
4.3 (3.8 - 4.6) 
4.5 (4.1 - 4.8) 
4.5 (4.2 - 4.8) 
 
.07 
.17 
.15 
Catastrophizingh 
Baseline 
2-week assessment 
Follow-up assessment 
 
29.3 (24.0 -34.5) 
25.4 (20.2 - 30.6) 
21.6 (16.4 - 26.8)** 
 
23.6 (18.5 - 28.7) 
16.4 (11.3 - 21.5)* 
15.8 (10.7 - 20.8)** 
 
.13 
.02† 
.12 
Anxiety-Traiti 
Baseline 
2-week assessment 
Follow-up assessment 
 
43.1 (38.1 - 48.2) 
39.4 (34.4 - 44.5) 
38.2 (33.1 - 43.2)* 
 
39.6 (34.6 - 44.5) 
37.6 (32.6 - 42.5) 
35.7 (30.7 - 40.6) 
 
.32 
.60 
.48 
Anxiety-Statei 
Baseline 
2-week assessment 
Follow-up assessment 
 
39.9 (35.4 - 44.9) 
35.2 (31.3 - 39.7) 
34.0 (30.2 - 38.3)* 
 
33.2 (29.6 - 37.3) 
32.8 (29.2 - 36.8) 
30.0 (26.7 - 33.7) 
 
.03† 
.39 
.14 
Pain anxietykj 
Baseline 
2-week assessment 
Follow-up assessment 
 
42.7 (34.4 - 51.0) 
37.6 (29.3 - 45.9) 
32.4 (24.1 - 40.7)*** 
 
33.9 (25.8 - 41.9) 
24.4 (16.3 - 32.4)** 
22.0 (13.9 - 30.1)*** 
 
.13 
.03† 
.08 
Depressionk 
Baseline 
2-week assessment 
Follow-up assessment 
 
7.1 (4.8 - 10.6) 
5.3 (3.5 - 7.9) 
5.0 (3.4 - 7.5) 
 
6.2 (4.2 - 9.1) 
5.5 (3.7 - 8.1) 
4.1 (2.8 - 6.1)* 
 
.62 
.92 
.48 
Impression of changel, n (%) 
2-week assessment 
Follow-up assessment 
 
13 (68) 
8 (42) 
 
13 (65) 
13 (65) 
 
.82 
.15 
Satisfactionm, n (%) 
2-week assessment 
Follow-up assessment 
 
11 (58) 
8 (42) 
 
14 (70) 
14 (70) 
 
.42 
.14 
25 
 
 
Table 3 – Pressure pain thresholds/tolerance by treatment group 
 Treatment group   
 Active tDCSa Sham tDCSa Difference between groups 
Outcomes n = 19 n = 20 P valueb 
PPT, gc 
Position no3 
Baseline 
2-week assessment 
Follow-up assessment 
Position no6 
Baseline 
2-week assessment 
Follow-up assessment 
Position no9 
Baseline 
2-week assessment 
Follow-up assessment 
 
 
112.6 (83.4 - 152.0) 
118.5 (87.4 - 160.7) 
108.6 (80.1 - 147.4) 
 
112.5 (84.3 - 150.)  
116.2 (86.7 - 155.7) 
125.8 (93.9 - 168.6) 
 
94.5 (69.4 - 128.9) 
84.7 (61.4 - 116.7) 
96.5 (70.5 - 132.3) 
 
 
120.4 (89.9 - 161.3)  
137.8 (102.4 - 185.4) 
149.5 (111.6 - 200.2) 
 
120.3 (90.5 - 159.9)  
169.0 (127.1 - 224.7) 
166.5 (125.6 - 220.5) 
 
111.4 (82.3 - 150.7) 
128.5 (94.5 - 174.6) 
130.3 (96.3 - 176.3) 
 
 
.75 
.48 
.14 
 
.74 
.07 
.17 
 
.45 
.07 
.18 
PPTol, gc 
Position no3 
Baseline 
2-week assessment 
Follow-up assessment 
Position no6 
Baseline 
2-week assessment 
Follow-up assessment 
Position no9 
Baseline 
2-week assessment 
Follow-up assessment 
 
 
94.5 (69.4 - 128.9)  
84.7 (61.4 - 116.7) 
96.5 (70.5 - 132.3) 
 
384.9 (291.5 - 508.5)  
364.3 (275.7 - 481.0) 
332.0 (251.4 - 438.7) 
 
327.7 (246.4 - 435.5) 
344.8 (258.5 - 460.0) 
357.1 (267.7 - 476.5) 
 
 
111.4 (82.3 - 150.7)  
128.5(94.5 - 174.6) 
130.3 (96.3 - 176.3) 
 
550.0 (420.4 - 718.9)  
488.8 (372.9 - 641.3) 
524.8 (400.3 - 688.4) 
 
425.8 (322.5 - 562.0) 
450.3 (340.1 - 596.4) 
433.1 (328.1 - 571.8) 
 
 
.45 
.07 
.18 
 
.07 
.13 
.02* 
 
.19 
.19 
.34 
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Table 4 – Blinding effectiveness by treatment group 
 
  Treatment group  
  Active tDCSa Sham tDCSa  
  n = 19 n = 20 P value b 
P
ar
ti
ci
p
an
ts
’ 
be
lie
ve
s 
Active 8 (42) 11 (55) 
0.5 
Sham 11 (58) 9 (45) 
O
p
er
at
or
’s
 
be
lie
ve
s 
Active 16 (84) 8 (40) 
0.008** 
Sham 3 (16) 12 (60) 
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Table 5 – Adverse events by treatment group 
 Treatment group   
 Active tDCSa Sham tDCSa  
Adverse events n = 19 n = 20 P value b 
Anodal tingling sensation 
Cathodal tingling sensation 
Cathodal pinching sensation 
Anodal burning sensation 
Cathodal burning sensation 
Anodal redness 
Cathodal redness 
Anodal heating sensation 
Anodal itching sensation 
15 (79) 
9 (47) 
0 
5 (26) 
12 (63) 
6 (32) 
12 (63) 
3 (16) 
4 (21) 
16 (80) 
17 (85) 
1 (5) 
2 (10) 
6 (30) 
2 (10) 
6 (30) 
2 (10) 
0 
.6 
.02* 
.5 
.2 
.04* 
.1 
.04* 
.5 
.05 
Fatigue 
Headache 
Scalp tenderness 
Dizziness 
Nausea 
Stomach aches 
Eye flash 
Gastric reflux 
Hot face 
5 (26) 
12 (63) 
2 (11) 
1 (5) 
4 (21) 
2 (11) 
0 
1 (5) 
1 (5) 
3 (15) 
12 (60) 
0 
2 (10) 
1 (5) 
1 (5) 
1 (5) 
1 (5) 
0 
.3 
.6 
.2 
.5 
.2 
.5 
.5 
.8 
.5 
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Figures 
 
Figure 1 – Participants’ selection and assessments 
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Figure 2 – Mean pain intensity during intercourse (NRS0-10) at baseline, post-treatment and 
follow-up assessments 
 
Tables and figures legends 
Figure 1 
There is no legend for Figure 1. 
 
Figure 2 
Asterisk indicates significant difference from baseline. 
* P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, and ns= non-significant difference; significant difference 
from baseline. 
 
Table 1 
aResults are reported as median (interquartile range) or frequency (percentage). 
 
Table 2 
aResults are reported as mean (95% confidence interval) or frequency (percentage); bMixed 
linear model for repeated measures; cMPQ (range, 0-74); dFSFI (range, 19-110); eFSDS (range, 
0-52); fGMSS (range, 19-110); gVPCQ (range, 0-6); hPCS (range, 0-52); iSTAI of Spielberger 
(range, 20-80); j(range, 0-100); kBDI (range, 0-63); lPGIC (range, 1-7) and mPGIC-Satisfaction 
(range, 0-10). 
30 
* P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001; significant difference from baseline. 
† P ≤ 0.05, †† P ≤ 0.01; significant difference between groups. 
 
Table 3 
PPT, Pressure pain thresholds; PPTol, Pressure pain tolerance. 
aResults are reported as mean (95% confidence interval); bMixed linear model for repeated 
measures; cPPT and PPTol measured by algometer (range, 0-1000). 
* P ≤ 0.05; significant difference between groups. 
 
Table 4 
aResults are reported as frequency (percentage); bChi-squared test. 
** P ≤ 0.01; significant difference between groups. 
 
Table 5 
aResults are reported as frequency (percentage); bChi-squared test. 
* P ≤ 0.05; significant difference between groups. 
